New WuXi/Lilly Deal Builds On Long Partnership
This article was originally published in PharmAsia News
WuXi and Lilly are building on a long history of collaboration by entering into a new partnership for the development in China of an experimental drug that addresses cardiovascular risk in patients with dyslipidemia, a huge unmet medical need in the country. The move also marks another step in WuXi’s flexible approach to international alliances.
You may also be interested in...
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.